check_circleStudy Completed

gastrointestinal stromal tumors

Regorafenib in subjects with gastrointestinal stromal tumors (GIST) who have progressed after standard therapy

Trial purpose

The objective of the trial is to provide regorafenib to subjects diagnosed with metastatic and / or unresectable GIST who have progressed after standard therapy.
Selected additional safety information on regorafenib will be collected and progression-free survival (PFS) will be estimated.

Key Participants Requirements

Sex

Both

Age

18 - 99 Years

Trial summary

Enrollment Goal
N/A
Trial Dates
null - Today
Phase
Phase 3
Could I Receive a placebo
No
Products
Stivarga (Regorafenib, BAY73-4506)
Accepts Healthy Volunteer
N/A

Trial design

An open-label Expanded Access Program of regorafenib in patients with gastrointestinal stromal tumors (GIST) after disease progression on or intolerance to imatinib and sunitinib
Trial Type
Expanded Access
Intervention Type
Drug
Trial Purpose
N/A
Allocation
N/A
Blinding
N/A
Assignment
N/A
Trial Arms
N/A